Clinical validity of clinical treatment score 5 (CTS5) for estimating risk of late recurrence in unselected, non-trial patients with early oestrogen receptor-positive breast cancer.

Breast Cancer Research and Treatment
Juliet RichmanIvana Sestak

Abstract

Clinical Treatment Score at 5 years (CTS5) is a prognostic tool to estimate distant recurrence (DR) risk after 5 years of endocrine therapy for postmenopausal women with oestrogen receptor-positive (ER-positive) breast cancer. The validity of CTS5 was tested in a retrospective cohort of patients diagnosed with early ER-positive breast cancer. The primary endpoint was DR in years 5-10. The primary analysis cohort consisted of postmenopausal women, with premenopausal women as a secondary analysis cohort. Cox regression models were used to determine the prognostic value of CTS5 and Kaplan-Meier curves were used with associated 10-year DR risks (%). 2428 women were included with a median follow-up of 13.4 years. The CTS5 was significantly prognostic in both postmenopausal (N = 1662, HR = 2.18 95% CI (1.78-2.67)) and premenopausal women (N = 766, HR = 1.84 95% CI (1.32-2.56)). The 10-year DR risks were 2.9% (1.9-4.5), 7.2% (5.3-9.9), and 12.9% (10.0-16.7) for low, intermediate and high risk in postmenopausal women and 3.8% (2.2-6.7), 6.9% (4.4-10.8), and 11.1% (7.4-16.5) in premenopausal women, respectively. The number of observed DRs was significantly greater than expected in those predicted to be at high risk by CTS5 but this disc...Continue Reading

References

Feb 13, 2014·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Martin FilipitsUNKNOWN Austrian Breast and Colorectal Cancer Study Group
Apr 19, 2015·Breast Cancer Research : BCR·Kathrin Strasser-WeipplPaul E Goss
Jun 7, 2016·The New England Journal of Medicine·Paul E GossWendy R Parulekar
Sep 20, 2017·Journal of the National Cancer Institute·Erik J BlokUNKNOWN IDEAL Study Group
Nov 9, 2017·The New England Journal of Medicine·Hongchao PanUNKNOWN EBCTCG
Apr 21, 2018·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Mitch DowsettJack Cuzick

❮ Previous
Next ❯

Citations

May 15, 2021·American Society of Clinical Oncology Educational Book·Ines Vaz-LuisVered Stearns

❮ Previous
Next ❯

Related Concepts

Related Feeds

Breast Cancer: Chemo-Resistance

Some cancers are difficult to treat and aggressive including the "triple-negative" breast cancer. This type of cancer is chemoresistant even before chemotherapy begins. Here are the latest discoveries chemo-resistance in breast cancer.